Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?

Area of Science:

• Nephrology
• Pharmacology
• Cardiovascular Medicine

Background:

• Chronic kidney disease (CKD) prevalence is rising globally, imposing significant economic and health burdens.
• Current CKD management primarily focuses on slowing disease progression due to a lack of specific causal treatments.
• Existing therapies, including antihypertensives and renin-angiotensin-aldosterone system (RAAS) blockers (ACEis and ARBs), only attenuate, not halt, renal failure progression.

Purpose of the Study:

• To review the available evidence on the renoprotective effects of aliskiren.
• To compare the potential renoprotective actions of aliskiren with those of ACE inhibitors (ACEis) and angiotensin II receptor blockers (ARBs).

Main Methods:

• Literature review of studies investigating aliskiren's effects on renal health.
• Comparative analysis of aliskiren's renoprotective mechanisms against established RAAS inhibitors (ACEis and ARBs).

Main Results:

• Aliskiren inhibits renin, the rate-limiting enzyme in the RAAS cascade.
• Theoretical advantages suggest aliskiren may offer enhanced renoprotection compared to ACEis and ARBs.
• Potential limitations of ACEis and ARBs, such as increased plasma renin activity, are discussed.

Conclusions:

• Aliskiren represents a novel therapeutic approach for CKD management by directly targeting renin.
• Evidence suggests aliskiren may provide superior renoprotective benefits over ACEis and ARBs.
• Further investigation into aliskiren's clinical efficacy in slowing CKD progression is warranted.